| HOME >> MEDICINE >> TECHNOLOGY |
Net income for the second quarter of 2011 included non-cash charges of $3.0 million in stock compensation expense associated with ASC 718 and $2.6 million of depreciation and amortization expense. Net income for the second quarter of 2010 included non-cash charges of $2.4 million in stock compensation expense associated with ASC 718 and $2.1 million of depreciation and amortization expense.
LUMINEX CORPORATIONREPORTABLE SEGMENT HIGHLIGHTS(in thousands, except percentages)Three Months EndedJune 30,Variance20112010($)(%)(unaudited)RevenueTechnology and strategic partnerships
$
36,211$
25,227$
,98444%Assays and related products
11,4278,0153,41243%Total Revenue
47,63833,24214,39643%Operating income (loss)Technology and strategic partnerships
11,5723,6167,956220%Assays and related products
(2,775)(1,351)(1,424)-105%Total Operating income
8,7972,2656,532288%Six Months EndedJune 30,Variance20112010($)(%)(unaudited)RevenueTechnology and strategic partnerships
$
8,146$
50,443$
7,70335%Assays and related products
22,76716,0516,71642%Total Revenue
90,91366,49424,41937%Operating income (loss)Technology and strategic partnerships
20,2287,91212,316156%Assays and related products
(3,137)(1,899)(1,238)-65%Total Operating income
17,0916,01311,078184%FINANCIAL OUTLOOK AND GUIDANCE The Company raises its 2011 annual revenue guidance to a range of $180 million to $185 million from $163 to $170 million. The updated range of annual revenue is an increase of between 27 to 31 percent over reported 2010 annual revenue and includes an anticipated contributio
'/>"/>
| SOURCE Luminex Corporation Copyright©2010 PR Newswire. All rights reserved |